Follow
Herd- or group-think in drug development:
"Large companies are the biggest contributors to this phenomenon, with an estimated 68% of the portfolios of the top 10 companies going after targets with a significant amount of herding. And one of the reasons mentioned for this is the increasing number of combination therapies (especially in oncology), where organizations want their own drug candidates in that mix, rather than relying on having their new drug dosed with somebody else’s."
